UPDATEDJul 28, 2026

NewsMeter/ the news, measured

TECHSK Hynix's near-15% plunge pulls Micron and Nvidia lower in premarket chip sell-offJul 28, 2026

ENERGYiPad Air M3 1TB cuts to $749 at Best Buy, erasing 40% of its sticker after Apple's price hikesJul 28, 2026

$ETHBitmine adds nearly 10,000 ETH to treasury, cumulative buybacks hit 11.6 million shares under $4 billion programJul 28, 2026

MACROSK Hynix shares deepen slide to 12% as selling pressure holdsJul 28, 2026

MACROSingapore birth rate hits post-independence lowJul 28, 2026

EARNINGSAI bond stress widens as Meta, Microsoft earnings approachJul 28, 2026

MACRONasdaq futures fall 0.5%, S&P 500 futures slip in pre-market tradeJul 28, 2026

ENERGYOver 1,000 Iran sanctions in place; Treasury pressure rated above bombs by U.S. officialsJul 28, 2026

TECHSK Hynix's near-15% plunge pulls Micron and Nvidia lower in premarket chip sell-offJul 28, 2026

ENERGYiPad Air M3 1TB cuts to $749 at Best Buy, erasing 40% of its sticker after Apple's price hikesJul 28, 2026

$ETHBitmine adds nearly 10,000 ETH to treasury, cumulative buybacks hit 11.6 million shares under $4 billion programJul 28, 2026

MACROSK Hynix shares deepen slide to 12% as selling pressure holdsJul 28, 2026

MACROSingapore birth rate hits post-independence lowJul 28, 2026

EARNINGSAI bond stress widens as Meta, Microsoft earnings approachJul 28, 2026

MACRONasdaq futures fall 0.5%, S&P 500 futures slip in pre-market tradeJul 28, 2026

ENERGYOver 1,000 Iran sanctions in place; Treasury pressure rated above bombs by U.S. officialsJul 28, 2026

Samsung Biologics tables CHF 1.46 billion all-cash bid for Switzerland's PolyPeptide Group

1.46 billion Swiss francs ($1.8 billion) is the all-cash figure South Korea's Samsung Biologics has placed on Switzerland's PolyPeptide Group. The offer was disclosed on Monday. Cash only: no equity component was attached to the…

By Mateo Fuentes·Jul 20, 2026·1 min read·markets

1.46 billion Swiss francs ($1.8 billion) is the all-cash figure South Korea's Samsung Biologics has placed on Switzerland's PolyPeptide Group. The offer was disclosed on Monday. Cash only: no equity component was attached to the bid.

Deal at a glance

Item	Detail
Offer price	CHF 1.46 billion
Dollar equivalent	$1.8 billion
Structure	All-cash
Acquirer	Samsung Biologics (South Korea)
Target	PolyPeptide Group (Switzerland)
Announced	Monday

The offer

CHF 1.46 billion converts to $1.8 billion. That is the full cash consideration Samsung Biologics has put on the table for PolyPeptide Group. No board recommendation from the Swiss company or closing timeline appeared in Monday's disclosure.

Share

Source: NewsMeter

© 2026 NewsMeter

→

Keep reading

Markets · INTCJul 27, 2026

Intel Corporation's overvaluation question surfaces in Seeking Alpha analysis

Markets · AMZNJul 27, 2026

Amazon files for 5,105-satellite constellation, targeting direct-to-device mobile by 2028

Markets · NVDAJul 27, 2026

Nvidia invests in Safe Superintelligence with terms undisclosed

Key takeaways

Samsung Biologics has made an all-cash offer of CHF 1.46 billion (about $1.8 billion) for Switzerland's PolyPeptide Group.
The bid was disclosed on Monday and contains no equity component.
Samsung Biologics is based in South Korea, while the target, PolyPeptide Group, is based in Switzerland.
Monday's disclosure included no board recommendation from PolyPeptide and no closing timeline.

Frequently asked

How much is Samsung Biologics offering for PolyPeptide Group?

Samsung Biologics is offering CHF 1.46 billion, equivalent to about $1.8 billion.

Is the offer cash or stock?

The offer is all-cash, with no equity component attached to the bid.

When was the offer announced?

The offer was disclosed on Monday.

Did PolyPeptide's board recommend the deal?

No board recommendation from the Swiss company appeared in Monday's disclosure.

Is there a timeline for closing the deal?

No closing timeline was included in Monday's disclosure.